MARKET

NERV

NERV

Minerva Neurosci
NASDAQ
4.770
-0.150
-3.05%
After Hours: 4.770 0 0.00% 16:10 07/07 EDT
OPEN
4.920
PREV CLOSE
4.920
HIGH
4.950
LOW
4.590
VOLUME
188.42K
TURNOVER
--
52 WEEK HIGH
12.46
52 WEEK LOW
1.590
MARKET CAP
222.23M
P/E (TTM)
-0.1639
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NERV last week (0629-0703)?
Weekly Report · 1d ago
Weekly Report: what happened at NERV last week (0622-0626)?
Weekly Report · 06/29 09:56
Weekly Report: what happened at NERV last week (0615-0619)?
Weekly Report · 06/22 10:02
Weekly Report: what happened at NERV last week (0608-0612)?
Weekly Report · 06/15 10:03
Weekly Report: what happened at NERV last week (0601-0605)?
Weekly Report · 06/08 10:00
Minerva Neurosciences releases corporate presentation on roluperidone for negative symptoms of schizophrenia
PUBT · 06/05 11:28
Minerva Neurosciences Updates Governance Following 2026 Shareholder Meeting
TipRanks · 06/04 21:12
Minerva Neurosciences shareholders approve charter amendments at annual meeting
PUBT · 06/04 20:08
More
About NERV
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.

Webull offers Minerva Neurosciences Inc stock information, including NASDAQ: NERV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NERV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NERV stock methods without spending real money on the virtual paper trading platform.